Claudine Isaacs, MD


Challenges in the Field of Hereditary Breast Cancer

Claudine Isaacs, MD, professor, medical Director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses some of the challenges physicians are facing in the field of hereditary breast cancer.

Clifford A. Hudis, MD


Dose-Dense Chemotherapy for Breast Cancer

Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.

Clifford A. Hudis, MD, FACP


Dr. Clifford A. Hudis on the Importance of In-Breast Response Rates in Triple-Negative Breast Cancer

Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.

Clifford Hudis, MD


The Relationship Between Obesity and Breast Cancer

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology, discusses the significance of the relationship between breast cancer and obesity.

Colin G. Evans, PhD


Preventing and Treating Bone Metastases in mCRPC

Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Colin Weekes, MD, PhD


Dr. Colin Weekes on Molecular Phenotyping in Pancreatic Cancer

Colin Weekes, MD, PhD, associate professor, Department of Medicine and Medical Oncology, University of Colorado, on molecular phenotyping in pancreatic cancer patients.

Constantine S. Tam, MD


Ibrutinib Plus Venetoclax Is a Potential Second-line Regimen in MCL

Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.

Craig Horbinski, MD, PhD


Recommendations for Treating Central Nervous System Cancers

In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.

Craig L. Slingluff, MD


The Rationale for the Administering the Seviprotimut-L Vaccine to Patients with Melanoma

Craig L. Slingluff, MD, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L vaccine in melanoma.

Craig L. Tendler, MD


The Mechanism of Action of Ibrutinib

Craig L. Tendler, MD, discusses the mechanism of action of ibrutinib in various tumor types.

Cristiana Sessa, MD


Targeted Therapies for Patients With Ovarian Cancer Who Have BRCA-Mutated Tumors

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses targeted therapies for <em>BRCA</em>1/2-mutated tumors.&nbsp;

Cristina Gasparetto, MD


Results for the Combination of Selinexor and Daratumumab in Multiple Myeloma

Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.

Cynthia Herrera


New Targeted Therapy in Acute Lymphocytic Leukemia: A Review of Blinatumomab in Relapsed/Refractory Acute Lymphocytic Leukemia

Acute lymphoblastic leukemia (ALL) is a relatively rare malignancy in adults, with an estimated 6250 new cases and 1450 deaths expected in the United States in 2015. Although most patients achieve complete remission with conventional combination chemotherapy regimens, at least two-thirds of high-risk patients relapse.2 While overall survival for children has significantly improved in the last 30 years, newly diagnosed adults continue to have a poor 5-year OS rate, approximating 35%, depending on age and risk factors.

Cynthia X. MA, MD, PhD


Challenges With Patient Selection for Extended Adjuvant Endocrine Therapy in Breast Cancer

Cynthia X. Ma, MD, PhD discusses the challenges with understanding treatment duration for adjuvant endocrine therapy in patients with breast cancer.

D. Ross Camidge, MD


MET as a Secondary Driver in Lung Cancer

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.

D. Ross Camidge, MD, PhD, University of Colorado


NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKI

Expert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.

Dale Chenoweth


Immune Checkpoint Inhibitors Show Promise in Glioblastoma Treatment

An emerging class of immune checkpoint blockade drugs has produced impressive benefits for patients in many solid tumor types. The class' success hints that these drugs ay be successful against central nervous system tumors as well, including glioblastoma.

Danae Delivanis, MD


Dr. Danae Delivanis on Pembrolizumab and Nivolumab in Metastatic Melanoma

Danae Delivanis, MD, endocrinologist, Mayo Clinic, on the use of pembrolizumab and nivolumab in the treatment of metastatic melanoma.

Daniel A. Pollyea, MD, MS


Is It Time to Bring Back the French American British Classification System?

Learning more about monocytic resistance to venetoclax is a new direction toward improving outcomes for patients with acute myeloid leukemia.

Daniel Catenacci, MD


Roundtable Discussion: Catenacci Compares Frontline Treatment for Patients With Gastric Cancer

The treatment landscape for gastric cancer is evolving. The use of biomarkers and implementation of testing to improve outcome later on in the course of treatment are being more important.

Daniel George, MD


Expert Discusses When to Perform PSMA PET Imaging for Metastatic CRPC

Daniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.

Daniel H. Fowler


The Challenges of GVHD in Patients with Lymphoma

Daniel H. Fowler, MD, discusses the challenges of graph-versus-host-disease (GVHD) in patients with high-risk lymphoma.

Daniel H. Fowler, MD


How T-rapa Cells Work

Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes how T-rapa cells work.

Daniel Hamstra, MD, PhD


Dr. Daniel Hamstra on the Benefits of Shorter Radiation Therapy Sessions for Prostate Cancer

&#8203;Daniel Hamstra, MD, PhD, radiation oncologist, Texas Center for Proton Therapy, Texas Oncology, discusses the benefits of shorter radiotherapy treatment sessions for patients with prostate cancer.

Daniel J. DeAngelo, MD, PhD


Overview of 4 FDA Approvals in Acute Myeloid Leukemia

Daniel J. DeAngelo, MD, PhD, associate professor at the Harvard School of Medicine and a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, highlighted the 4 FDA approvals in the last year for the treatment of patients with acute myeloid leukemia.